Tinlarebant (LBS-008)

Name: Tinlarebant (LBS-008) in Stargardt disease type 1: Clinical presentation - signs and symptoms
Published: 2026-09-14T15:39:06-04:00

Stargardt disease type 1

Manufacturer: Belite Bio
Regulatory submission: NDA submitted June 2026
Launch: Anticipated in March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Clinical presentation - signs and symptoms

3 evidence topics · 1 source

Central vision: progressive visual loss

“The most common symptom of Stargardt disease is a slow loss of central vision in both eyes.” (opens the source at this quote in a new tab)

Central vision: scotomas

“Gray, black, or hazy spots in the center of your vision” (opens the source at this quote in a new tab)

Light sensitivity and adaptation

“Sensitivity to light” (opens the source at this quote in a new tab)
“Needing more time for your eyes to adjust between light and dark places” (opens the source at this quote in a new tab)